BioSpace News Archive

By 2060, it’s estimated that 14 million people will be living with Alzheimer’s disease (AD), 40 percent of whom will experience psychotic symptoms.

CASI Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, announced that the Company is planning to submit an Investigational New Drug application to the U.S. Food and Drug Administration for CID-103 for the treatment of antibody-mediated rejection in kidney transplant recipients by the end of 2024.

Novotech, an internationally renowned full-service clinical Contract Research Organization (CRO) known for its collaboration with biotech firms to accelerate the development of innovative therapeutics across all phases, has today published a leading industry report, Radiopharmaceuticals - Global Clinical Trial Landscape.

Kewaunee Scientific Corporation announced results for its fourth quarter and its fiscal year ended April 30, 2024.

Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced the closing of its public offering of 1,100,000 shares of its common stock at an offering price of $1.00 per share.

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the US Food and Drug Administration (“FDA”) approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.

The New England Journal of Medicine has published results from a positive phase 3 study of Dupixent in children aged one to 11 years with eosinophilic esophagitis.

TriSalus Life Sciences® Inc. announced the expiration and results of its previously announced exchange offer and consent solicitation relating to its warrants identified in the Prospectus/Offer to Exchange that forms a part of the Registration Statement.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine(NEJM) has published results from a positive Phase 3 trial for Dupixent® (dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (EoE).

Nxera Pharma Co. Ltd, announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million to Nxera.